10.18
+0.04(+0.39%)
Currency In USD
| Previous Close | 10.14 |
| Open | 10.19 |
| Day High | 10.46 |
| Day Low | 10.11 |
| 52-Week High | 13.16 |
| 52-Week Low | 6.19 |
| Volume | 692,218 |
| Average Volume | 1.88M |
| Market Cap | 571.46M |
| PE | -40.72 |
| EPS | -0.25 |
| Moving Average 50 Days | 9.53 |
| Moving Average 200 Days | 8.96 |
| Change | 0.04 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $37.23 as of November 02, 2025 at a share price of $10.18. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $1,034.55 as of November 02, 2025 at a share price of $10.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewswire Inc.
Oct 29, 2025 11:30 AM GMT
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Z
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
GlobeNewswire Inc.
Oct 27, 2025 11:30 AM GMT
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providin
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 06, 2025 9:51 PM GMT
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company